<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cardiac <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> (CA) is associated with increased risk of sudden <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy improves survival in patients with <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> due to other etiologies, the benefit of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in patients with CA is unclear in large part due to limited data on the precise mechanism of sudden <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> and selection of patients with cardiac <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: The objective was to determine the benefit of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in cardiac <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We reviewed <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implant indications, procedures, and therapies, of CA patients evaluated at Mayo Clinic between 2000 and 2009 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 53 patients with CA (33 AL, 10 senile, 9 familial, and 1 AA) who underwent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation were included </plain></SENT>
<SENT sid="5" pm="."><plain>Indication for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation was for primary prevention of sudden <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> in 41 (77%) patients and secondary prevention in 12 (23%) patients </plain></SENT>
<SENT sid="6" pm="."><plain>The rate of appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks was 32% in the first year and was observed almost exclusively in AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> patients, occurring in 15 patients (12 AL <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, 2 senile, 1 AA) </plain></SENT>
<SENT sid="7" pm="."><plain>Appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks were more frequent in patients with prior sudden <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> or sustained <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> (secondary prevention indication), and less frequent in patients who presented with decreased ejection fraction or <z:hpo ids='HP_0001279'>syncope</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: A high rate of appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks was observed especially in patients with AL-type <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>However, appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy did not translate into overall survival benefit, suggesting that selection of patients with CA who might be candidates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> is imprecise </plain></SENT>
</text></document>